Cargando…
BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors
Rhabdoid tumors (RT) are malignant neoplasms of early childhood. Despite intensive therapy, survival is poor and new treatment approaches are required. The only recurrent mutations in these tumors affect SMARCB1 and less commonly SMARCA4, both subunits of the chromatin remodeling complex SWItch/Sucr...
Autores principales: | Krämer, Katja F., Moreno, Natalia, Frühwald, Michael C., Kerl, Kornelius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536025/ https://www.ncbi.nlm.nih.gov/pubmed/28714904 http://dx.doi.org/10.3390/ijms18071537 |
Ejemplares similares
-
Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
por: Moreno, Natalia, et al.
Publicado: (2017) -
ATRT-13. DIFFERENT CELLS OF ORIGIN PAVE THE WAY FOR MOLECULAR HETEROGENEITY IN RHABDOID TUMORS
por: Graf, Monika, et al.
Publicado: (2020) -
The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells
por: Kerl, Kornelius, et al.
Publicado: (2013) -
Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors
por: Graf, Monika, et al.
Publicado: (2022) -
Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors
por: Nemes, Karolina, et al.
Publicado: (2022)